Kostmann syndrome or infantile genetic agranulocytosis, part one: Celebrating 50 years of clinical and basic research on severe congenital neutropenia

Congenital neutropenia in man was first reported 50 years ago by the Swedish paediatrician Rolf Kostmann. He coined the term “infantile genetic agranulocytosis” for this condition, which is now known as Kostmann syndrome. Recent studies have demonstrated a lack of antibacterial peptides and severe periodontitis in these patients despite recombinant growth factor treatment. Moreover, an increased degree of apoptosis of myeloid progenitor cells in the bone marrow has been shown.

[1]  V. Everts,et al.  Role of Polymorphonuclear Leukocyte-Derived Serine Proteinases in Defense against Actinobacillus actinomycetemcomitans , 2006, Infection and Immunity.

[2]  D. Sack,et al.  Improved outcome in shigellosis associated with butyrate induction of an endogenous peptide antibiotic. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[3]  T. Hökfelt,et al.  The antimicrobial peptide cathelicidin protects the urinary tract against invasive bacterial infection , 2006, Nature Medicine.

[4]  J. Adams,et al.  Toll-Like Receptor Triggering of a Vitamin D-Mediated Human Antimicrobial Response , 2006, Science.

[5]  Philip S Rosenberg,et al.  The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy. , 2005, Blood.

[6]  J. Palmblad,et al.  Neutrophil elastase and granulocyte colony-stimulating factor receptor mutation analyses and leukemia evolution in severe congenital neutropenia patients belonging to the original Kostmann family in northern Sweden. , 2006, Haematologica.

[7]  M. Weichenthal,et al.  Reduced Paneth cell α-defensins in ileal Crohn's disease , 2005 .

[8]  S. Orrenius,et al.  Apoptosis: a basic biological phenomenon with wide‐ranging implications in human disease , 2005, Journal of internal medicine.

[9]  C. Bevins,et al.  Mechanisms of Disease: defensins in gastrointestinal diseases , 2005, Nature Clinical Practice Gastroenterology &Hepatology.

[10]  M. Schrappe,et al.  Heterogeneous expression pattern of pro‐ and anti‐apoptotic factors in myeloid progenitor cells of patients with severe congenital neutropenia treated with granulocyte colony‐stimulating factor , 2005, British journal of haematology.

[11]  G. Carlsson.  Kostmann syndrome : A clinical and pathophysiological study , 2004 .

[12]  J. Palmblad,et al.  Kostmann syndrome: severe congenital neutropenia associated with defective expression of Bcl-2, constitutive mitochondrial release of cytochrome c, and excessive apoptosis of myeloid progenitor cells. , 2004, Blood.

[13]  H. G. Boman,et al.  Antibacterial peptides: basic facts and emerging concepts , 2003, Journal of internal medicine.

[14]  O. Katoh,et al.  Dysregulation of transcriptions in primary granule constituents during myeloid proliferation and differentiation in patients with severe congenital neutropenia , 2003, Journal of leukocyte biology.

[15]  R. Zetterström.  Kostmann disease—infantile genetic agranulocytosis: historical views and new aspects , 2002, Acta paediatrica.

[16]  Göran Carlsson,et al.  Deficiency of antibacterial peptides in patients with morbus Kostmann: an observation study , 2002, The Lancet.

[17]  M. Zasloff.  Antimicrobial peptides of multicellular organisms , 2002, Nature.

[18]  A. Fasth,et al.  Infantile genetic agranulocytosis, morbus Kostmann: Presentation of six cases from the original “Kostmann family” and a review , 2001, Acta paediatrica.

[19]  J. Calafat,et al.  Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3. , 2001, Blood.

[20]  E. Chi,et al.  Impaired survival of bone marrow hematopoietic progenitor cells in cyclic neutropenia. , 2001, Blood.

[21]  M. Freedman,et al.  Management of kostmann syndrome in the g‐csf era , 2000, British journal of haematology.

[22]  E. Chi,et al.  Myelokathexis, a congenital disorder of severe neutropenia characterized by accelerated apoptosis and defective expression of bcl-x in neutrophil precursors. , 2000, Blood.

[23]  N. Bishop,et al.  High incidence of significant bone loss in patients with severe congenital neutropenia (Kostmann's syndrome). , 1997, The Journal of pediatrics.

[24]  L. Iselius,et al.  Spatial distribution of the gene for infantile genetic agranulocytosis. , 1984, Human heredity.

[25]  R. Parmley,et al.  Congenital dysgranulopoietic neutropenia: clinical, serologic, ultrastructural, and in vitro proliferative characteristics. , 1980, Blood.

[26]  R. Kostman.  Infantile genetic agranulocytosis. A review with presentation of ten new cases. , 1975, Acta paediatrica Scandinavica.

[27]  H. Cutting,et al.  INFANTILE GENETIC AGRANULOCYTOSIS. , 1965, Pediatrics.

[28]  R. Kostmann.  Infantile Genetic Agranulocytosis (Agranulocytosis infantilis hereditaria) A New Recessive Lethal Disease in Man , 1956 .